Risankizumab-rzaa

Category: Skin Care



Risankizumab-rzaa Overview

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).[5] Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union,[4] the United States,[3][6] and Canada[7] for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. In Japan,...

Read more Risankizumab-rzaa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Risankizumab

Recent Risankizumab-rzaa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Risankizumab-rzaa
  • Injection: 150mg/ml, 75mg/0.83ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Risankizumab-rzaa or a similar ingredient: (1 result)